Effect of GW2016, a dual inhibitor of erbB-2 and EGFR tyrosine receptor kinases, on EGF induced receptor tyrosine autophosphorylation state and downstream signaling pathway.

被引：0
|
作者：
Xia, W [1 ]
Mullin, R [1 ]
Keith, B [1 ]
Rusnak, D [1 ]
Rhodes, N [1 ]
Gilmer, T [1 ]
Lackey, K [1 ]
Knight, B [1 ]
Lucas, S [1 ]
Spector, N [1 ]
机构：
[1] GlaxoSmithKline, Res Triangle Pk, NC USA
来源：
CLINICAL CANCER RESEARCH | 2001年 / 7卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
570
引用
收藏
页码：3768S / 3768S
页数：1
相关论文
共 16 条
  • [1] EGF RECEPTOR AND ERBB-2 TYROSINE KINASE DOMAINS CONFER CELL SPECIFICITY FOR MITOGENIC SIGNALING
    DIFIORE, PP
    SEGATTO, O
    TAYLOR, WG
    AARONSON, SA
    PIERCE, JH
    SCIENCE, 1990, 248 (4951) : 79 - 83
  • [2] Discovery and profile of GW572016, a dual reversible EGFR/ErbB-2 tyrosine kinase inhibitor.
    Mullin, RJ
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2003, 226 : U2 - U2
  • [3] The pan-ErbB inhibitor dacomitinib but not the dual EGFR/ErbB2 inhibitor labatinib disrupts membrane localization of the EGFR family of receptor tyrosine kinases
    Jathak, Maitreyee K.
    Steele, Thomas M.
    Siddiqui, Salma
    Mooso, Benjamin A.
    D'Abronzo, Leandro S.
    Drake, Christiana M.
    Ghosh, Paramita M.
    CANCER RESEARCH, 2018, 78 (13)
  • [4] The effects of the novel, reversible epidermal growth factor Receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo
    Rusnak, DW
    Lackey, K
    Affleck, K
    Wood, ER
    Alligood, KJ
    Rhodes, N
    Keith, BR
    Murray, DM
    Knight, WB
    Mullin, RJ
    Gilmer, TM
    MOLECULAR CANCER THERAPEUTICS, 2001, 1 (02) : 85 - 94
  • [5] LIGAND-INDEPENDENT TYROSINE PHOSPHORYLATION OF EGF RECEPTOR AND THE ERBB-2/NEU PROTO-ONCOGENE PRODUCT IS INDUCED BY HYPEROSMOTIC SHOCK
    KING, CR
    BORRELLO, I
    PORTER, L
    COMOGLIO, P
    SCHLESSINGER, J
    ONCOGENE, 1989, 4 (01) : 13 - 18
  • [6] Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
    Xia, WL
    Mullin, RJ
    Keith, BR
    Liu, LH
    Ma, H
    Rusnak, DW
    Owens, G
    Alligood, KJ
    Spector, NL
    ONCOGENE, 2002, 21 (41) : 6255 - 6263
  • [7] Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
    Wenle Xia
    Robert J Mullin
    Barry R Keith
    Lei-Hua Liu
    Hong Ma
    David W Rusnak
    Gary Owens
    Krystal J Alligood
    Neil L Spector
    Oncogene, 2002, 21 : 6255 - 6263
  • [8] Targeting EGFR/HER2 signaling pathway by a dual receptor tyrosine kinase inhibitor BIBW2992 for radiosensitization in murine urothelial carcinoma
    Yeh, Chih-Hsien
    Cheng, Jason Chia-Hsien
    Tsai, Yu-Chieh
    Tuan, Tsung Fan
    Ho, Pei-Yin
    Pu, Yeong-Shiau
    Cheng, Ann-Lii
    CANCER RESEARCH, 2012, 72
  • [9] Prevention of DMBA-induced mammary gland tumors in mice by a dual-function inhibitor of JAK3 and EGF receptor tyrosine kinases
    Sahin, Kazim
    Yabas, Mehmet
    Orhan, Cemal
    Tuzcu, Mehmet
    Sahin, Taha K.
    Ozercan, Ibrahim H.
    Qazi, Sanjive
    Uckun, Fatih M.
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2020, 24 (04) : 379 - 387
  • [10] Chemoprevention of 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch by topical application of a dual inhibitor of epidermal growth factor receptor (EGFR) and ErbB2 tyrosine kinases
    Sun, Zheng
    Sood, Sandeep
    Li, Ning
    Yang, Peiying
    Newman, Robert A.
    Yang, Chung S.
    Chen, Xiaoxin
    ORAL ONCOLOGY, 2008, 44 (07) : 652 - 657
12